Loading organizations...
§ Venture Capital · Mendham, NJ, USA
Multi-stage venture capital firm investing in patient-focused biotechnology and life sciences companies developing therapeutic solutions.
Barer & Son Capital is a multi-stage venture capital firm, investing in patient-focused companies developing next-generation therapeutic and healthcare solutions. The firm targets innovations addressing unmet medical needs, collaborating with strong leadership teams and co-investors. They deploy capital and guidance to foster groundbreaking life science ventures.
Co-founded in 2017 by Dr. Sol Barer and Josh Barer, the firm emerged from the Barer Family Office. Dr. Sol Barer brings substantial biotechnology leadership experience; his son, Josh Barer, focuses on venture capital. Their insight was to combine deep industry knowledge with strategic investment, cultivating disruptive life science innovations.
Barer & Son Capital partners with companies creating novel solutions for global patients. The firm’s vision centers on accelerating transformative medicines and technologies, providing crucial capital and guidance to promising enterprises. They commit to bringing impactful advancements to market, enhancing patient quality of life and addressing critical health challenges.
Barer & Son Capital has 2 tracked investments across 2 companies. The latest tracked deal is $35.0M Series A in AsclepiX Therapeutics in June 2020.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jun 1, 2020 | AsclepiX Therapeutics | $35.0M Series A | Perceptive Advisors | Rapha Capital Management |
| Jun 17, 2019 | Viela Bio | $75.0M Series B | HBM Healthcare Investments | Cormorant Asset Management, Goldman Sachs, Temasek, Terra Magnum Capital Partners, Viking Global Investors |